Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. is engaged in the commercial sales of Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Also, Co. markets branded Ampyra (dalfampridine), an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP) approved to improve walking in adults with multiple sclerosis. We show 38 historical shares outstanding datapoints in our coverage of ACOR's shares outstanding history.
Understanding the changing numbers of ACOR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACOR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACOR by allowing them to research ACOR shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
